Hikma Pharmaceuticals PLC logo

Hikma Pharmaceuticals PLC (HIKl)

Market Closed
CBOE CBOE
- Market Cap
28.53 P/E Ratio
4.22% Div Yield
- Volume
1.91 Eps
Want to track HIKl and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

HIKl pays dividends to its shareholders, with the most recent payment made on Apr 30, 2026. The next estimated payment will be in 1 month ago on Apr 30, 2026 for a total of 0.35517 GBX.
The last earnings report, released on Feb 26, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0467%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on LSE (GBX).

Hikma Pharmaceuticals PLC (HIKl) FAQ

On which exchange is it traded?

Hikma Pharmaceuticals PLC is listed on CBOE.

What is its stock symbol?

The ticker symbol is HIKl.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4.22%.

What is its market cap?

As of today, no market cap data is available.

Has Hikma Pharmaceuticals PLC ever had a stock split?

No, there has never been a stock split.

Hikma Pharmaceuticals PLC Profile

Specialty Retail Industry
Consumer Discretionary Sector
Said Samih Taleb Darwazah CEO
CBOE Exchange
GB00B0LCW083 ISIN
GB Country
9,500 Employees
19 Mar 2026 Last Dividend
- Last Split
- IPO Date

Overview

Hikma Pharmaceuticals PLC is a global pharmaceutical company founded in 1978 with its headquarters located in London, United Kingdom. The company specializes in the development, manufacturing, marketing, and selling of a wide array of pharmaceutical products. It operates through three primary segments: Injectables, Generics, and Branded. These segments cumulatively cater to a broad spectrum of healthcare needs, encompassing both hospital and retail markets in the United Kingdom, Europe, North America, the Middle East, North Africa, and other international territories.

Products and Services

  • Injectables

    This segment focuses on the provision of generic injectable products primarily for hospital use. These injectables cover various therapeutic areas, making Hikma a crucial player in the healthcare system, especially in acute care settings where injectables are often required for immediate patient treatment.

  • Generics

    Hikma's Generics segment is dedicated to offering oral and other non-injectable generic products targeted toward the retail market. This includes a wide range of cost-effective treatments for patients, ensuring accessibility to essential medications without compromising on quality.

  • Branded

    The Branded segment deals with branded generics and in-licensed products for both retail and hospital markets. These products provide reliable, high-quality alternatives to branded pharmaceuticals, catering to a variety of therapeutic areas and facilitating a broad reach across different healthcare settings.

In addition to these primary segments, Hikma Pharmaceuticals PLC offers a diverse portfolio across several therapeutic areas such as respiratory, oncology, and pain management. The company's comprehensive product lineup is available in multiple dosage forms including solid, semi-solid, liquid, and injectable, enabling it to meet a wide range of patient needs and preferences.

Contact Information

Address: 1 New Burlington Place
Phone: 44 20 7399 2760